Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

Final draft guidance

Final draft guidance (PDF 109 KB)

Committee papers (PDF 4.51 MB)

Equality impact assessment (downloadable version) (PDF 123 KB)

Final scope (PDF 165 KB)

Final stakeholder list (PDF 167 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 209 KB)

Equality impact assessment (scoping) (PDF 127 KB)

Draft scope post referral (PDF 181 KB)

Draft matrix of consultees and commentators post referral (PDF 218 KB)